H
Hiroyuki Odaka
Researcher at Takeda Pharmaceutical Company
Publications - 97
Citations - 2527
Hiroyuki Odaka is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Insulin & Diabetes mellitus. The author has an hindex of 29, co-authored 97 publications receiving 2449 citations. Previous affiliations of Hiroyuki Odaka include Osaka University & Hirosaki University.
Papers
More filters
Journal ArticleDOI
Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by Pioglitazone
Junichi Sakamoto,Hiroyuki Kimura,Shinji Moriyama,Hiroyuki Odaka,Yu Momose,Yasuo Sugiyama,Hidekazu Sawada +6 more
TL;DR: Results showed that pioglitazone significantly increased the apoA-I secretion from the human hepatoma cell line HepG2 and binding assay indicated that the transactivation of hPPARgamma1 or hPParalpha by piog Litazone is due to direct binding of piog litazone to each subtype.
Journal ArticleDOI
Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin.
Yoshihiro Ogawa,Hiroaki Masuzaki,Kiminori Hosoda,Megumi Aizawa-Abe,Junko Suga,Michio Suda,Ken Ebihara,Hidenori Iwai,Naoki Matsuoka,Noriko Satoh,Hiroyuki Odaka,Hisao Kasuga,Yukio Fujisawa,Gen Inoue,Haruo Nishimura,Yasunao Yoshimasa,Kazuwa Nakao +16 more
TL;DR: Evidence is provided that leptin is an adipocyte-derived antidiabetic hormone in vivo and its pathophysiologic and therapeutic implications in diabetes are suggested and suggested.
Journal ArticleDOI
Overexpression of GPR40 in Pancreatic β-Cells Augments Glucose-Stimulated Insulin Secretion and Improves Glucose Tolerance in Normal and Diabetic Mice
Kae Nagasumi,Ritsuko Esaki,Kimihiko Iwachidow,Yoshitaka Yasuhara,Kazuhiro Ogi,Hideyuki Tanaka,Mitsugu Nakata,Takashi Yano,Kozo Shimakawa,Shigehisa Taketomi,Koji Takeuchi,Hiroyuki Odaka,Yoshihiko Kaisho +12 more
TL;DR: The results suggest that G PR40 may have a role in regulating glucose-stimulated insulin secretion and plasma glucose levels in vivo and that pharmacological activation of GPR40 may provide a novel insulin secretagogue beneficial for the treatment of type 2 diabetes.
Journal ArticleDOI
Novel 5-Substituted 2,4-Thiazolidinedione and 2,4-Oxazolidinedione Derivatives as Insulin Sensitizers with Antidiabetic Activities
Yu Momose,Tsuyoshi Maekawa,Tohru Yamano,Mitsuru Kawada,Hiroyuki Odaka,Hitoshi Ikeda,Takashi Sohda +6 more
TL;DR: The antidiabetic effects of this compound are considered to be due to its potent agonistic activity for peroxisome proliferator-activated receptor gamma (EC(50) = 8.87 nM).
Journal ArticleDOI
Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes.
T Matsuo,Hiroyuki Odaka,H Ikeda +2 more
TL;DR: A new disaccharidase inhibitor, AO-128, showed 190-3900-fold more potent inhibition of purified rat small intestine sucrase-isomaltase (S-1) complex and 23-33-fold greater inhibition of semipurified porcine small intestine disacchcharidases than acarbose, and is useful as an adjunct to the dietary management of obesity and diabetes.